deltatrials
Terminated PHASE1 NCT00464113

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)

Sponsor: Exelixis

Conditions Chronic Myeloid Leukemia Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions XL228
Updated 7 times since 2017 Last updated: Aug 19, 2015 Started: May 31, 2007 Primary completion: Dec 31, 2010 Completion: Apr 30, 2011

A PHASE1 clinical study on Chronic Myeloid Leukemia and Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, this trial is terminated or withdrawn. The trial is conducted by Exelixis and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exelixis
Data source: Exelixis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ann Arbor, United States
  • • Houston, United States
  • • Los Angeles, United States
  • • San Francisco, United States
  • • Tampa, United States
  • • Washington D.C., United States